{"success":true,"data":{"pressRelease":{"id":"165020","rtpr_id":"nGNE7Y509M-20261009","ticker":"ROPC","exchange":"","all_tickers":["ROPC"],"title":"FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer","author":"Globe Newswire","published_at":"2026-10-09T05:00:00.233Z","article_body":"* FDA approval is based on results from the landmark phase III ATOMIC study,\npublished in The New England Journal of Medicine, which showed Tecentriq plus\nchemotherapy reduced the risk of disease recurrence or death by 50% compared\nto chemotherapy alone(1)\n* First approved adjuvant immunotherapy regimen for stage III dMMR colon\ncancer, positioning Tecentriq as a new post-surgery standard of care \n* Nearly 25% of all colon cancers are diagnosed at stage III, and almost one\nin three patients with stage III colon cancer experience a recurrence within\nfive years(2,3)\n* Approval marks the twelfth indication for Tecentriq in the US\nBasel, 9 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today\nthat the US Food and Drug Administration (FDA) has approved Tecentriq®\n(atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs)\nin combination with a fluoropyrimidine and oxaliplatin for the adjuvant\ntreatment of stage III deficient DNA mismatch repair (dMMR) colon cancer, a\ntype of tumour characterised by high mutation rates. This approval marks the\ntwelfth indication for Tecentriq in the US.\n\n“This approval provides a new adjuvant treatment option for people with\nstage III dMMR colon cancer who face a high risk of disease recurrence,”\nsaid Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of\nGlobal Product Development. “Tecentriq combined with chemotherapy has the\npotential to become the new standard of care as the first approved\nimmunotherapy-based regimen for this setting.”\n\n“Until now, the adjuvant standard of care for stage III colon cancer has not\ndiffered based on mismatch repair status,” said Frank A. Sinicrope, MD,\nProfessor of Oncology at the Mayo Clinic and US Principal Investigator for the\nAlliance ATOMIC trial. “This milestone represents an important therapeutic\nadvance that leverages immunotherapy to target the specific biology of dMMR\nstage III colon cancer after surgical resection. By reducing the risk of\ndisease recurrence or death by 50%, atezolizumab plus chemotherapy is a\npractice-changing regimen that can improve clinical outcomes of this group of\npatients living with colon cancer, one of the most common cancers and a\nleading cause of cancer-related death.”\n\nThe FDA approval is based on the landmark phase III ATOMIC study, recently\npublished in The New England Journal of Medicine\n(https://www.globenewswire.com/Tracker?data=vvqPuukimWHh5Rbx2S2zg53e2L5XCedAq1110cEaZzChtmaOoxCNzhYlKlZBnOk9MQmpWM1AHGyEsqTNuBwTlfqdvTyqUptuNc8AkVTQtmQQWhL90xSUDuVeomCfT4UJW5oBI9s60_Q9QOgExI24DMWpHke_OBxNnaK4kVKQ-J4=).\nATOMIC demonstrated that adding Tecentriq to modified (m)FOLFOX6 chemotherapy\nreduced the risk of disease recurrence or death by 50%, compared to\nchemotherapy alone for people with stage III dMMR colon cancer, as determined\nby an immunohistochemistry test, such as the VENTANA® MMR RxDx Panel.(1) The\n36-month disease-free survival was 86% for Tecentriq combined with mFOLFOX6\ncompared with 76% in the mFOLFOX6 alone group. The safety profile was\nconsistent with previous studies of Tecentriq and mFOLFOX6.(1)\n\nColon cancer remains one of the world's most common and deadliest tumours.(4)\nOver one million people are diagnosed globally each year, and nearly 25% of\nall colon cancers are diagnosed at stage III.(2-4) Despite surgery and\nchemotherapy, nearly 30% of stage III patients experience disease recurrence\nwithin five years.(2,3) Approximately 15% of colon cancer patients present\nwith dMMR or microsatellite instability-high (MSI-H) tumours, which indicate a\nhigher mutation rate and thus have the potential to respond to\nimmunotherapy.(5)\n\nRoche is pursuing further regulatory filings for Tecentriq, including with the\nEuropean Medicines Agency, to bring this immunotherapy-based adjuvant option\nto patients with dMMR colon cancer worldwide as soon as possible.\n\nAbout the ATOMIC study\nATOMIC (A021502, NCT02912559\n(https://www.globenewswire.com/Tracker?data=QJDh-0_BolF1tFhYqOQ0VselzqQey9Mm_NhrUxf8Z_5lqG-KD-8o4dnosfHzAiYaavt3E8pWu8FCG3E_mC2UQh9LOsuOosMKEqkeQMiNsp_WEQ5XoU6sDPMYo5So6siO))\nis a phase III, randomised, open-label, multicentre study investigating the\naddition of Tecentriq® (atezolizumab) to modified (m)FOLFOX6 chemotherapy (a\ncombination of folinic acid, fluorouracil, and oxaliplatin) in patients with\nstage III colon cancer who have a deficiency in DNA mismatch repair (dMMR).\nThe trial enrolled 712 patients. Participants were randomised 1:1 to receive\neither mFOLFOX6 plus Tecentriq for 12 cycles (six months) followed by\nTecentriq monotherapy for 13 cycles (an additional six months), or mFOLFOX6\nalone for 12 cycles. The primary endpoint is disease-free survival (DFS).\n\nThe global study in the US was sponsored by the US National Cancer Institute\n(NCI), part of the National Institutes of Health, and led by the Alliance for\nClinical Trials in Oncology (Alliance) with participation from other\nNCI-funded National Clinical Trials Network (NCTN) groups. Genentech, a member\nof the Roche Group, provided support for the study through a Cooperative\nResearch and Development Agreement between NCI and Genentech. The trial was\nled globally by Frank A. Sinicrope, MD, Professor of Oncology at the Mayo\nClinic and US Principal Investigator within the Alliance. German participation\nin this major international academic collaboration was enabled through close\ncooperation between the Alliance and the AIO-Studien-gGmbH, in partnership\nwith the AIO (Arbeitsgemeinschaft Internistische Onkologie) of the German\nCancer Society (Deutsche Krebsgesellschaft, DKG), under the national\nleadership of Prof. Dr. Anke Reinacher-Schick (Ruhr-Universität Bochum).\nAIO-affiliated study sites enrolled patients during the later recruitment\nphase, ensuring access for eligible patients in Germany.\n\nAbout Tecentriq® (atezolizumab)\nTecentriq is a monoclonal antibody designed to bind with a protein called\nPD-L1, which is expressed on tumour cells and tumour-infiltrating immune\ncells, blocking its interactions with both PD-1 and B7.1 receptors. By\ninhibiting PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq\nmay also affect normal cells.\n\nTecentriq has been approved for some of the most aggressive and\ndifficult-to-treat forms of cancer, and is the first PD-(L)1 cancer\nimmunotherapy available in both subcutaneous and intravenous formulations.\n\nAbout Roche in oncology\nFor over 60 years, Roche has delivered transformative medicines and\ndiagnostics, redefining the treatment of some of the most challenging cancers.\nDriven by a vision of a future where cancer can be cured, we focus our efforts\non cancers with the highest societal impact and where we bring deep expertise,\nincluding breast, lung, and blood cancers, while pursuing breakthrough\ninnovation in other areas of unmet need. Our pipeline features a diverse array\nof modalities, from small molecules and antibodies to next-generation ADCs and\nallogeneic CAR T-cell therapies. By advancing best-in-class precision\nmedicine, pioneering novel combinations, and leveraging key technologies and\npartnerships, Roche tackles oncology's toughest challenges with the goal of\ndelivering life-changing outcomes for people with cancer.\n\nAbout Roche \nRoche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to\nprevent, stop and cure diseases by uniting leading science and technology\nacross diagnostics, medicines and digital solutions.\n\nRoche was founded in Basel, Switzerland in 1896 and today is a leading\nprovider of transformative medicines and diagnostics for millions of people in\nover 150 countries around the world. It is dedicated to tackling healthcare\nchallenges that place the greatest strain on patients, families, communities\nand healthcare systems. Across its Diagnostics and Pharmaceutical divisions,\nRoche focuses on areas including oncology, neurology, cardiovascular and\nmetabolic diseases, ophthalmology, infectious diseases and immunology with the\naim of providing real and positive change for patients, the people they love\nand the professionals who care for them.\n\nGenentech in the United States is a fully owned subsidiary in the Roche Group.\nRoche is the majority shareholder in Chugai Pharmaceutical, a major innovator\nin the Japanese therapeutic antibody market.\n\nFor more information, please visit www.roche.com.\n\nAll trademarks used or mentioned in this release are protected by law.\n\nReferences\n[1] Sinicrope F, et al. Atezolizumab plus FOLFOX for Stage III Mismatch\nRepair–Deficient Colon Cancer. N Engl J Med. 2026;394:1155-1166.\n[2] Gonzalez B, et al. Analyzing recurrence in colorectal cancer: Is a five\nyears follow-up enough? Annals of Oncology. 2024;35(1);11.\n[3] Nors J et al. Incidence of Recurrence and Time to Recurrence in Stage I to\nIII Colorectal Cancer: A Nationwide Danish Cohort Study. JAMA Oncology.\n2024;10(1):54–62.\n[4] World Health Organization. Cancer [Internet; cited 2026 October].\nAvailable from: https://www.who.int/news-room/fact-sheets/detail/cancer.\n[5] Boland CR, et al. Microsatellite Instability in Colorectal Cancer.\nGastroenterology. 2010;138:2073–2087.\n\nRoche Global Media Relations\nPhone: +41 61 688 88 88 / e-mail: media.relations@roche.com\n\n Tristan Schmitz Phone: +41 79 529 70 35      Lorena Corfas Phone: +41 79 568 24 95     \n Simon Goldsborough Phone: +44 797 32 72 915  Karsten Kleine Phone: +41 79 461 86 83    \n Kirti Pandey Phone: +41 79 398 38 53         Yvette Petillon Phone: +41 79 961 92 50   \n Irène Stephan Phone: +41 79 377 83 75        Albert Thottiyil Phone: +41 79 775 66 12  \n\nRoche Investor Relations\n\n Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com      Dr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com   \n Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com                                                                                     \n\nInvestor Relations North America\n\n Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com    \n\nAttachment\n*     Media&Investor Release FDA approval for Tecentriq Tecentriq Hybreza\nEnglish\n(https://ml-eu.globenewswire.com/Resource/Download/a5b4c07d-4ed0-455b-b98d-c25f9598a247)","article_body_html":"","raw_payload":{"data":{"id":"nGNE7Y509M-20261009","title":"FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer","author":"Globe Newswire","ticker":"ROPC","created":"2026-10-09T05:00:00.233Z","tickers":["ROPC"],"exchange":"","article_body":"* FDA approval is based on results from the landmark phase III ATOMIC study,\npublished in The New England Journal of Medicine, which showed Tecentriq plus\nchemotherapy reduced the risk of disease recurrence or death by 50% compared\nto chemotherapy alone(1)\n* First approved adjuvant immunotherapy regimen for stage III dMMR colon\ncancer, positioning Tecentriq as a new post-surgery standard of care \n* Nearly 25% of all colon cancers are diagnosed at stage III, and almost one\nin three patients with stage III colon cancer experience a recurrence within\nfive years(2,3)\n* Approval marks the twelfth indication for Tecentriq in the US\nBasel, 9 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today\nthat the US Food and Drug Administration (FDA) has approved Tecentriq®\n(atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs)\nin combination with a fluoropyrimidine and oxaliplatin for the adjuvant\ntreatment of stage III deficient DNA mismatch repair (dMMR) colon cancer, a\ntype of tumour characterised by high mutation rates. This approval marks the\ntwelfth indication for Tecentriq in the US.\n\n“This approval provides a new adjuvant treatment option for people with\nstage III dMMR colon cancer who face a high risk of disease recurrence,”\nsaid Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of\nGlobal Product Development. “Tecentriq combined with chemotherapy has the\npotential to become the new standard of care as the first approved\nimmunotherapy-based regimen for this setting.”\n\n“Until now, the adjuvant standard of care for stage III colon cancer has not\ndiffered based on mismatch repair status,” said Frank A. Sinicrope, MD,\nProfessor of Oncology at the Mayo Clinic and US Principal Investigator for the\nAlliance ATOMIC trial. “This milestone represents an important therapeutic\nadvance that leverages immunotherapy to target the specific biology of dMMR\nstage III colon cancer after surgical resection. By reducing the risk of\ndisease recurrence or death by 50%, atezolizumab plus chemotherapy is a\npractice-changing regimen that can improve clinical outcomes of this group of\npatients living with colon cancer, one of the most common cancers and a\nleading cause of cancer-related death.”\n\nThe FDA approval is based on the landmark phase III ATOMIC study, recently\npublished in The New England Journal of Medicine\n(https://www.globenewswire.com/Tracker?data=vvqPuukimWHh5Rbx2S2zg53e2L5XCedAq1110cEaZzChtmaOoxCNzhYlKlZBnOk9MQmpWM1AHGyEsqTNuBwTlfqdvTyqUptuNc8AkVTQtmQQWhL90xSUDuVeomCfT4UJW5oBI9s60_Q9QOgExI24DMWpHke_OBxNnaK4kVKQ-J4=).\nATOMIC demonstrated that adding Tecentriq to modified (m)FOLFOX6 chemotherapy\nreduced the risk of disease recurrence or death by 50%, compared to\nchemotherapy alone for people with stage III dMMR colon cancer, as determined\nby an immunohistochemistry test, such as the VENTANA® MMR RxDx Panel.(1) The\n36-month disease-free survival was 86% for Tecentriq combined with mFOLFOX6\ncompared with 76% in the mFOLFOX6 alone group. The safety profile was\nconsistent with previous studies of Tecentriq and mFOLFOX6.(1)\n\nColon cancer remains one of the world's most common and deadliest tumours.(4)\nOver one million people are diagnosed globally each year, and nearly 25% of\nall colon cancers are diagnosed at stage III.(2-4) Despite surgery and\nchemotherapy, nearly 30% of stage III patients experience disease recurrence\nwithin five years.(2,3) Approximately 15% of colon cancer patients present\nwith dMMR or microsatellite instability-high (MSI-H) tumours, which indicate a\nhigher mutation rate and thus have the potential to respond to\nimmunotherapy.(5)\n\nRoche is pursuing further regulatory filings for Tecentriq, including with the\nEuropean Medicines Agency, to bring this immunotherapy-based adjuvant option\nto patients with dMMR colon cancer worldwide as soon as possible.\n\nAbout the ATOMIC study\nATOMIC (A021502, NCT02912559\n(https://www.globenewswire.com/Tracker?data=QJDh-0_BolF1tFhYqOQ0VselzqQey9Mm_NhrUxf8Z_5lqG-KD-8o4dnosfHzAiYaavt3E8pWu8FCG3E_mC2UQh9LOsuOosMKEqkeQMiNsp_WEQ5XoU6sDPMYo5So6siO))\nis a phase III, randomised, open-label, multicentre study investigating the\naddition of Tecentriq® (atezolizumab) to modified (m)FOLFOX6 chemotherapy (a\ncombination of folinic acid, fluorouracil, and oxaliplatin) in patients with\nstage III colon cancer who have a deficiency in DNA mismatch repair (dMMR).\nThe trial enrolled 712 patients. Participants were randomised 1:1 to receive\neither mFOLFOX6 plus Tecentriq for 12 cycles (six months) followed by\nTecentriq monotherapy for 13 cycles (an additional six months), or mFOLFOX6\nalone for 12 cycles. The primary endpoint is disease-free survival (DFS).\n\nThe global study in the US was sponsored by the US National Cancer Institute\n(NCI), part of the National Institutes of Health, and led by the Alliance for\nClinical Trials in Oncology (Alliance) with participation from other\nNCI-funded National Clinical Trials Network (NCTN) groups. Genentech, a member\nof the Roche Group, provided support for the study through a Cooperative\nResearch and Development Agreement between NCI and Genentech. The trial was\nled globally by Frank A. Sinicrope, MD, Professor of Oncology at the Mayo\nClinic and US Principal Investigator within the Alliance. German participation\nin this major international academic collaboration was enabled through close\ncooperation between the Alliance and the AIO-Studien-gGmbH, in partnership\nwith the AIO (Arbeitsgemeinschaft Internistische Onkologie) of the German\nCancer Society (Deutsche Krebsgesellschaft, DKG), under the national\nleadership of Prof. Dr. Anke Reinacher-Schick (Ruhr-Universität Bochum).\nAIO-affiliated study sites enrolled patients during the later recruitment\nphase, ensuring access for eligible patients in Germany.\n\nAbout Tecentriq® (atezolizumab)\nTecentriq is a monoclonal antibody designed to bind with a protein called\nPD-L1, which is expressed on tumour cells and tumour-infiltrating immune\ncells, blocking its interactions with both PD-1 and B7.1 receptors. By\ninhibiting PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq\nmay also affect normal cells.\n\nTecentriq has been approved for some of the most aggressive and\ndifficult-to-treat forms of cancer, and is the first PD-(L)1 cancer\nimmunotherapy available in both subcutaneous and intravenous formulations.\n\nAbout Roche in oncology\nFor over 60 years, Roche has delivered transformative medicines and\ndiagnostics, redefining the treatment of some of the most challenging cancers.\nDriven by a vision of a future where cancer can be cured, we focus our efforts\non cancers with the highest societal impact and where we bring deep expertise,\nincluding breast, lung, and blood cancers, while pursuing breakthrough\ninnovation in other areas of unmet need. Our pipeline features a diverse array\nof modalities, from small molecules and antibodies to next-generation ADCs and\nallogeneic CAR T-cell therapies. By advancing best-in-class precision\nmedicine, pioneering novel combinations, and leveraging key technologies and\npartnerships, Roche tackles oncology's toughest challenges with the goal of\ndelivering life-changing outcomes for people with cancer.\n\nAbout Roche \nRoche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to\nprevent, stop and cure diseases by uniting leading science and technology\nacross diagnostics, medicines and digital solutions.\n\nRoche was founded in Basel, Switzerland in 1896 and today is a leading\nprovider of transformative medicines and diagnostics for millions of people in\nover 150 countries around the world. It is dedicated to tackling healthcare\nchallenges that place the greatest strain on patients, families, communities\nand healthcare systems. Across its Diagnostics and Pharmaceutical divisions,\nRoche focuses on areas including oncology, neurology, cardiovascular and\nmetabolic diseases, ophthalmology, infectious diseases and immunology with the\naim of providing real and positive change for patients, the people they love\nand the professionals who care for them.\n\nGenentech in the United States is a fully owned subsidiary in the Roche Group.\nRoche is the majority shareholder in Chugai Pharmaceutical, a major innovator\nin the Japanese therapeutic antibody market.\n\nFor more information, please visit www.roche.com.\n\nAll trademarks used or mentioned in this release are protected by law.\n\nReferences\n[1] Sinicrope F, et al. Atezolizumab plus FOLFOX for Stage III Mismatch\nRepair–Deficient Colon Cancer. N Engl J Med. 2026;394:1155-1166.\n[2] Gonzalez B, et al. Analyzing recurrence in colorectal cancer: Is a five\nyears follow-up enough? Annals of Oncology. 2024;35(1);11.\n[3] Nors J et al. Incidence of Recurrence and Time to Recurrence in Stage I to\nIII Colorectal Cancer: A Nationwide Danish Cohort Study. JAMA Oncology.\n2024;10(1):54–62.\n[4] World Health Organization. Cancer [Internet; cited 2026 October].\nAvailable from: https://www.who.int/news-room/fact-sheets/detail/cancer.\n[5] Boland CR, et al. Microsatellite Instability in Colorectal Cancer.\nGastroenterology. 2010;138:2073–2087.\n\nRoche Global Media Relations\nPhone: +41 61 688 88 88 / e-mail: media.relations@roche.com\n\n Tristan Schmitz Phone: +41 79 529 70 35      Lorena Corfas Phone: +41 79 568 24 95     \n Simon Goldsborough Phone: +44 797 32 72 915  Karsten Kleine Phone: +41 79 461 86 83    \n Kirti Pandey Phone: +41 79 398 38 53         Yvette Petillon Phone: +41 79 961 92 50   \n Irène Stephan Phone: +41 79 377 83 75        Albert Thottiyil Phone: +41 79 775 66 12  \n\nRoche Investor Relations\n\n Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com      Dr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com   \n Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com                                                                                     \n\nInvestor Relations North America\n\n Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com    \n\nAttachment\n*     Media&Investor Release FDA approval for Tecentriq Tecentriq Hybreza\nEnglish\n(https://ml-eu.globenewswire.com/Resource/Download/a5b4c07d-4ed0-455b-b98d-c25f9598a247)"},"type":"article","timestamp":"2026-10-09T05:00:00.331393524Z","server_sent_at_ms":1791522000331},"received_at":"2026-10-09T05:00:00.469Z","source_url":null},"analysis":{"id":"153418","press_release_id":"165020","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":[],"eventType":"fda_approval","narrative":"The FDA approved Roche's Tecentriq (atezolizumab) plus fluoropyrimidine and oxaliplatin as adjuvant treatment for stage III dMMR colon cancer — the twelfth US indication for Tecentriq and the first approved adjuvant immunotherapy regimen for this setting.\n\nThe approval rests on the Phase 3 ATOMIC study, which showed Tecentriq plus mFOLFOX6 reduced the risk of disease recurrence or death by 50% versus chemotherapy alone, with 36-month disease-free survival of 86% vs 76%.\n\nWith roughly 15% of colon cancer patients carrying dMMR/MSI-H tumors and ~25% of colon cancers diagnosed at stage III, the approval creates a meaningful new standard-of-care market; Roche is pursuing further filings with the EMA.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Practice-changing adjuvant approval extends Tecentriq franchise into stage III dMMR colon cancer with a 50% recurrence-risk reduction."},"keyFigures":{"drugName":"Tecentriq (atezolizumab) / Tecentriq Hybreza","phaseOfTrial":"Phase 3","customDimensions":{"indications_count_us":12,"atomic_trial_enrollment":712,"dfs_36_month_control_arm":"76%","recurrence_risk_reduction":"50%","dfs_36_month_tecentriq_arm":"86%"}},"quotedText":"Tecentriq combined with chemotherapy has the potential to become the new standard of care as the first approved immunotherapy-based regimen for this setting.","namedEntities":{"people":[{"name":"Levi Garraway","role":"Roche Chief Medical Officer and Head of Global Product Development"},{"name":"Frank A. Sinicrope","role":"Professor of Oncology, Mayo Clinic; US Principal Investigator for Alliance ATOMIC trial"},{"name":"Anke Reinacher-Schick","role":"German national study leadership, Ruhr-Universität Bochum"}],"products":["Tecentriq (atezolizumab)","Tecentriq Hybreza","mFOLFOX6","VENTANA MMR RxDx Panel"],"companies":[{"name":"Roche","ticker":"ROPC","relationship":"filer"},{"name":"Genentech","relationship":"Roche subsidiary; study supporter"},{"name":"National Cancer Institute (NCI)","relationship":"study sponsor"},{"name":"Alliance for Clinical Trials in Oncology","relationship":"trial lead"},{"name":"Chugai Pharmaceutical","relationship":"Roche majority-owned subsidiary"}],"dollarAmounts":[]},"materialImpact":{"score":4,"reasoning":"FDA approval of a new adjuvant indication for Roche's blockbuster immunotherapy Tecentriq, based on a Phase 3 study showing a 50% reduction in recurrence/death risk. Expands the drug to twelfth US indication and positions it as a new standard of care, though limited to the dMMR subset (~15% of colon cancer patients)."},"tickerRelevance":{"others":[{"ticker":"RHHBY","relevance":"OTCQX listing of the same filer"},{"ticker":"RO","relevance":"SIX listing of the same filer"}],"primary":"ROPC"},"globalImportance":55,"audienceRelevance":45,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mega-cap pharma","eventGravity":"FDA approval of new indication for blockbuster drug","marketSizeNote":"dMMR subset (~15% of stage III colon cancer) limits TAM","householdBrandBoost":true}},"event_type":"fda_approval","event_type_secondary":null,"sentiment":"bullish","material_impact_score":4,"narrative":"The FDA approved Roche's Tecentriq (atezolizumab) plus fluoropyrimidine and oxaliplatin as adjuvant treatment for stage III dMMR colon cancer — the twelfth US indication for Tecentriq and the first approved adjuvant immunotherapy regimen for this setting.\n\nThe approval rests on the Phase 3 ATOMIC study, which showed Tecentriq plus mFOLFOX6 reduced the risk of disease recurrence or death by 50% versus chemotherapy alone, with 36-month disease-free survival of 86% vs 76%.\n\nWith roughly 15% of colon cancer patients carrying dMMR/MSI-H tumors and ~25% of colon cancers diagnosed at stage III, the approval creates a meaningful new standard-of-care market; Roche is pursuing further filings with the EMA.","key_figures":{"drugName":"Tecentriq (atezolizumab) / Tecentriq Hybreza","phaseOfTrial":"Phase 3","customDimensions":{"indications_count_us":12,"atomic_trial_enrollment":712,"dfs_36_month_control_arm":"76%","recurrence_risk_reduction":"50%","dfs_36_month_tecentriq_arm":"86%"}},"named_entities":{"people":[{"name":"Levi Garraway","role":"Roche Chief Medical Officer and Head of Global Product Development"},{"name":"Frank A. Sinicrope","role":"Professor of Oncology, Mayo Clinic; US Principal Investigator for Alliance ATOMIC trial"},{"name":"Anke Reinacher-Schick","role":"German national study leadership, Ruhr-Universität Bochum"}],"products":["Tecentriq (atezolizumab)","Tecentriq Hybreza","mFOLFOX6","VENTANA MMR RxDx Panel"],"companies":[{"name":"Roche","ticker":"ROPC","relationship":"filer"},{"name":"Genentech","relationship":"Roche subsidiary; study supporter"},{"name":"National Cancer Institute (NCI)","relationship":"study sponsor"},{"name":"Alliance for Clinical Trials in Oncology","relationship":"trial lead"},{"name":"Chugai Pharmaceutical","relationship":"Roche majority-owned subsidiary"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-09T05:00:08.255Z","global_importance":55,"audience_relevance":45,"importance_components":{"tickerTier":"mega-cap pharma","eventGravity":"FDA approval of new indication for blockbuster drug","marketSizeNote":"dMMR subset (~15% of stage III colon cancer) limits TAM","householdBrandBoost":true}},"durationMs":7741,"modelName":"glm-5.3-flashx"}}